Observational studyBMC anesthesiology2026
Comparative effectiveness of dexmedetomidine and meperidine for the treatment of postanesthetic shivering: a propensity score-matched retrospective cohort study.
Observational study in BMC anesthesiology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundPostanesthetic shivering (PAS) is a common and distressing complication in the post-anesthesia care unit (PACU). Meperidine has traditionally been used for PAS treatment, but interest in non-opioid alternatives has increased. We compared the effectiveness and safety of dexmedetomidine versus meperidine for the treatment of PAS.
methodsThis retrospective cohort study included 484 adult patients who developed PAS in the PACU after surgery between January and December 2024 and received intravenous dexmedetomidine or meperidine as the initial treatment. The primary outcome was treatment failure, defined as the need for rescue anti-shivering medication before PACU discharge. Secondary outcomes included hypotension, bradycardia, postoperative nausea and vomiting, clinically significant respiratory depression, PACU length of stay, and PACU fentanyl consumption. After 1:1 propensity score matching, 149 matched pairs were analyzed.
resultsIn the matched cohort, dexmedetomidine was associated with a lower rate of treatment failure than meperidine (3.4% vs. 10.1%; OR 0.33, 95% CI 0.12-0.92; p = 0.033). Hypotension was more frequent in the dexmedetomidine group (6.7% vs. 1.3%; OR 5.00, 95% CI 1.10-22.82; p = 0.038). No clear between-group differences were found in bradycardia, postoperative nausea and vomiting, PACU length of stay, or fentanyl consumption, and no documented clinically significant respiratory depression occurred in either group. Sensitivity analyses showed similar results for the primary outcome.
conclusionIn patients with PAS in the PACU, dexmedetomidine was associated with a lower risk of treatment failure than meperidine, but a higher risk of hypotension. Dexmedetomidine may be an effective alternative when appropriate hemodynamic monitoring is available. CLINICAL
trial registrationNot applicable.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.